1. Home
  2. DKI vs APVO Comparison

DKI vs APVO Comparison

Compare DKI & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DKI

DarkIris Inc. Class A Ordinary Shares

HOLD

Current Price

$5.91

Market Cap

10.1M

Sector

N/A

ML Signal

HOLD

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

HOLD

Current Price

$4.86

Market Cap

8.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DKI
APVO
Founded
2018
2016
Country
Hong Kong
United States
Employees
19
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1M
8.3M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
DKI
APVO
Price
$5.91
$4.86
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
184.9K
26.3K
Earning Date
05-11-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.13
EPS
N/A
N/A
Revenue
N/A
$3,114,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$0.50
52 Week High
$11.80
$13.11

Technical Indicators

Market Signals
Indicator
DKI
APVO
Relative Strength Index (RSI) 71.90 50.82
Support Level $4.82 $4.29
Resistance Level $6.80 $5.66
Average True Range (ATR) 0.80 0.33
MACD 0.03 0.02
Stochastic Oscillator 57.21 65.17

Price Performance

Historical Comparison
DKI
APVO

About DKI DarkIris Inc. Class A Ordinary Shares

Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: